Washington University SPORE in Pancreatic Cancer

项目总结 华盛顿大学在胰腺癌方面的卓越研究专门项目(孢子)是一个 高度转化性癌症研究项目完全聚焦于这种疾病最致命的形式--胰腺 导管腺癌(PDAC)。我们优秀的调查人员在基础和基础方面拥有互补的专业知识 临床研究，我们的团队利用个人在免疫学、癌症生物学、药物开发、 基因组学和临床护理，以开发PDAC的新诊断和治疗方法。 该孢子申请包括三个研究项目，一个行政核心(核心A)，两个共享- 资源核心[生物质学家核心(核心B)和生物统计和生物信息学核心(核心C)]，以及 发展研究(DRP)和职业提升(CEP)计划。与我们的外部合作 (EAB)和内部(IAB)顾问委员会，我们特意选择了具有最大影响潜力的项目 PDAC患者的转归。WUSM和UPenn的基础研究导致了 在三个研究项目之后，所有这些项目都以研究人员发起的PDAC治疗试验为特色。 所有被认为最有可能产生翻译影响的项目，在他们的 接近。这一免疫学主题充分利用了机构优势，并突出了我们团队的专业知识和 在这一领域处于领先地位。到目前为止，免疫和代谢疗法越来越成功 对于控制其他癌症类型，在PDAC中没有效果。我们的项目负责人已经做出了值得注意的 阐明PDAC免疫耐药和耐药机制的研究进展 并制定了几个具有克服这些障碍的潜力的令人兴奋的战略。这个项目的三个项目 应用程序的设计具有在5年内改变临床实践的巨大潜力。 项目1：使用CD11b激动剂使PDAC对免疫治疗有反应 项目2.PDAC对新抗原疫苗的抗药性机制 项目3：将应激诱导的MK2作为治疗胰腺癌的新策略 我们的长期目标是改善被诊断为PDAC的患者的存活率和生活质量。至 为了实现这一目标，我们将促进机构和机构间的合作研究，重点是 翻译。我们预计，没有一种单一的方法可以解决PDAC问题，并完全致力于支持 开发新的研究概念以及非常有前途的年轻研究人员。我们的孢子会 提供胰腺癌特定资源的途径，以促进这项任务。

PROJECT SUMMARY The Washington University Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical studies, and our teams leverage individual expertise in immunology, cancer biology, drug development, genomics, and clinical care to develop novel diagnostic and therapeutic approaches for PDAC. This SPORE application includes three research projects, an administrative core (Core A), two shared- resource cores [Biospecimen Core (Core B) and Biostatistics and Bioinformatics Core (Core C)], and developmental research (DRP) and career enhancement (CEP) programs. In collaboration with our External (EAB) and Internal (IAB) Advisory Boards, we intentionally selected projects with the greatest potential to impact the outcome for patients with PDAC. Basic research at WUSM and UPenn has led to the development of the following three research projects, all of which feature innovative investigator-initiated therapeutic trials for PDAC. All projects deemed to have the most potential for translational impact and share an immunologic theme in their approach. This immunologic theme leverages institutional strengths and highlights our team’s expertise and leadership in this field. Thus far, the immunologic and metabolic therapies that have been increasingly successful for controlling other cancer types have not been impactful in PDAC. Our project leaders have made noteworthy contributions to elucidate the mechanisms underlying this immunologic resistance and drug resistance in PDAC and developed several exciting strategies with potential to overcome these obstacles. The three projects in this application are designed to have significant potential to change clinical practice within 5 years. Project 1. Employing CD11b-agonists to render PDAC responsive to immunotherapy Project 2. Mechanisms of Resistance to Neoantigen Vaccines in PDAC Project 3. Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer Our long-term goals are to improve the survival and the quality of life of patients diagnosed with PDAC. To achieve this goal, we will promote institutional and inter-institutional collaborative research, with an emphasis on translation. We anticipate that no singular approach will solve PDAC and fully commit to supporting the development of novel research concepts as well as highly promising young investigators. Our SPORE will provide access to pancreatic cancer–specific resources to facilitate this mission.